ClinicalTrials.Veeva

Menu
C

Coastal Research Associates, LLC | Roswell, GA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bimatoprost
Latanoprost
Netarsudil
AR-13324
RVL-1201
AR-12286
Betamethasone Sodium Phosphate
DE-126
PG043
Brinzolamide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 36 total trials

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Enrolling
Open-angle Glaucoma
Ocular Hypertension
Other: Sham Administration
Drug: AGN-193408 SR

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonst...

Enrolling
Ocular Hypertension
Glaucoma, Open-Angle
Drug: Test - Bimatoprost 0.01% Ophthalmic Solution
Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting
Glaucoma
Ocular Hypertension
Drug: Rhopressa®
Drug: T4090 0.3%

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hyper...

Invitation-only
Open-Angle Glaucoma
Ocular Hypertension
Drug: Bimatoprost SR
Other: Standard of Care

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Enrolling
Open Angle Glaucoma
Ocular Hypertension
Drug: AR-17043 Ophthalmic Solution
Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POA...

Active, not recruiting
Primary Open Angle Glaucoma (POAG)
Primary Open Angle Glaucoma of Both Eyes
Drug: Experimental: QLS-111 ophthalmic solution, (0.015%)
Drug: Experimental: QLS-111 ophthalmic solution, (0.03%)

Trial sponsors

Aerie Pharmaceuticals logo
Allergan logo
AbbVie logo
R
S
S
A
Alcon logo
A
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems